Overview
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in de novo living donor renal transplantation.
Eligibility
Key Inclusion Criteria:
- Able to understand the study requirements and provide written informed consent before and study assessment is performed
- Male or female patients ≥ 18 to 60 years of age
- Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor
Key Exclusion Criteria:
- Women of child-bearing potential
- Subjects with a history of cancer
- Donor-specific Antibody